Cumberland Pharmaceuticals (CPIX) AI Stock Analysis

• Market Cap: $39.79M
• Dividend Yield: N/A
• Average Volume (3M): 27.29K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.60
• Revenue Growth: 12.21%
• EPS Growth: 69.91%
• Country: US
• Employees: 91
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.13
• Shares Outstanding: 14,959,937
• 10 Day Avg. Volume: 30,352
• 30 Day Avg. Volume: 27,288
• PEG Ratio: -1.13
• Price to Book (P/B): 1.46
• Price to Sales (P/S): 0.88
• P/FCF Ratio: -42.08
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 1.07
• Enterprise Value/Gross Profit: 1.26
• Enterprise Value/Ebitda: 16.42
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $2.50 ▲(26.26% Upside)

Cumberland Pharmaceuticals' overall stock score is primarily influenced by its financial performance challenges and bearish technical indicators. The positive sentiment from the earnings call, driven by strategic partnerships and revenue growth, provides some support, but valuation concerns and operational inefficiencies weigh heavily on the score.

Cumberland Pharmaceuticals Business Overview & Revenue Model

Company Description

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

How the Company Makes Money

Cumberland Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products to hospitals, healthcare providers, and distributors. The company has established a revenue model that includes direct sales, distribution agreements, and partnerships with other pharmaceutical companies. Significant revenue streams arise from its marketed products, particularly in the areas of pain management and critical care. Additionally, the company may receive royalties or milestone payments from collaborations in research and development, further enhancing its earnings potential.

Cumberland Pharmaceuticals Financial Statement Overview

Summary

Cumberland Pharmaceuticals faces significant challenges in profitability and revenue growth, as evidenced by negative margins and declining revenues. While there is some improvement in leverage and cash flow metrics, the company needs to address operational inefficiencies and enhance profitability to achieve sustainable financial health.

Income Statement

Cumberland Pharmaceuticals shows a declining revenue trend with a negative revenue growth rate of -1.89% in the TTM. The company has consistently reported negative net profit margins, with the TTM net profit margin at -8.06%. Despite a strong gross profit margin of 84.49% in the TTM, the negative EBIT and EBITDA margins indicate operational inefficiencies and challenges in managing operating expenses.

Balance Sheet

The company's debt-to-equity ratio improved to 0.39 in the TTM from 0.90 in the previous year, indicating a reduction in leverage. However, the return on equity remains negative, reflecting ongoing profitability challenges. The equity ratio is relatively stable, suggesting a balanced asset structure, but the negative ROE highlights the need for improved profitability.

Cash Flow

Cumberland Pharmaceuticals has shown improvement in cash flow metrics, with a positive operating cash flow and a high free cash flow to net income ratio of 0.98 in the TTM. However, the free cash flow growth rate is negative, indicating potential challenges in sustaining cash flow generation. The operating cash flow to net income ratio of 0.28 suggests moderate cash flow efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	41.28M	37.87M	39.55M	42.01M	35.99M	37.44M
Gross Profit	34.88M	31.28M	33.49M	32.89M	27.17M	28.79M
EBITDA	2.68M	182.42K	2.49M	332.92K	-857.83K	-1.56M
Net Income	-3.33M	-6.48M	-6.28M	-5.57M	-3.51M	-3.34M
Balance Sheet
Total Assets	65.90M	75.58M	81.78M	92.93M	84.46M	96.46M
Cash, Cash Equivalents and Short-Term Investments	15.20M	17.96M	18.32M	19.76M	27.04M	24.75M
Total Debt	10.24M	20.57M	18.43M	20.96M	16.06M	19.26M
Total Liabilities	40.10M	53.04M	52.52M	56.95M	41.86M	49.59M
Stockholders Equity	26.12M	22.85M	29.60M	36.27M	42.81M	46.99M
Cash Flow
Free Cash Flow	6.71M	-791.90K	5.64M	6.38M	5.99M	3.30M
Operating Cash Flow	6.83M	-612.19K	6.09M	8.45M	6.34M	5.42M
Investing Cash Flow	-1.66M	57.84K	-105.69K	-13.67M	-501.89K	-1.76M
Financing Cash Flow	-7.44M	196.90K	-7.42M	-2.06M	-3.55M	-7.12M

Cumberland Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPIX, the sentiment is Negative. The current price of 1.98 is below the 20-day moving average (MA) of 3.07, below the 50-day MA of 3.22, and below the 200-day MA of 4.05, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 19.91 is Positive, neither overbought nor oversold. The STOCH value of 1.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CPIX.

Cumberland Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CPIX	51 Neutral	$39.79M	-12.47	-13.08%	―	12.21%	69.91%
ASRT	50 Neutral	$69.79M	-1.60	-38.40%	―	-11.42%	89.01%
RMTI	47 Neutral	$33.93M	―	-8.65%	―	-6.79%	61.56%
SCYX	41 Neutral	$26.45M	-1.11	-53.29%	―	-65.77%	38.61%
IXHL	39 Underperform	$118.01M	-0.25	-381.09%	―	616.67%	-22.13%
KALA	31 Underperform	$5.28M	-0.11	-708.34%	―	―	51.27%

Cumberland Pharmaceuticals Corporate Events

Cumberland Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

Cumberland Pharmaceuticals Inc. recently held an earnings call that conveyed a generally positive sentiment, highlighting strategic partnerships and international expansion as key drivers of growth. The company reported strong revenue growth and clinical progress, although these were slightly tempered by shipment delays and increased competition. Overall, the call reflected more highlights than lowlights, suggesting a positive outlook for the company.

Cumberland Pharmaceuticals Reports Revenue Growth and Strategic Expansions

Cumberland Pharmaceuticals Inc., headquartered in Tennessee, is a specialty pharmaceutical company focused on developing, acquiring, and commercializing products for hospital acute care, gastroenterology, and oncology markets. The company’s portfolio includes several FDA-approved brands aimed at improving patient care.

Cumberland Pharmaceuticals’ Promising Phase II Study on Ifetroban for IPF

Cumberland Pharmaceuticals Inc. is conducting a Phase II clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)’. The study aims to evaluate the safety and efficacy of oral Ifetroban, a drug designed to prevent and treat lung fibrosis, in patients suffering from IPF.

Cumberland Pharmaceuticals Partners with RedHill for Talicia

On October 20, 2025, Cumberland Pharmaceuticals announced a strategic partnership with RedHill Biopharma to jointly commercialize Talicia®, an FDA-approved treatment for Helicobacter pylori infection. This collaboration involves forming a new company where RedHill contributes Talicia assets and Cumberland invests $4 million, taking charge of distribution and sales. The agreement aims to leverage Cumberland’s sales force to enhance Talicia’s market presence, with both companies sharing revenues and operational responsibilities. Talicia, featuring high eradication rates and low resistance, is now a first-line treatment option in updated guidelines, with patent protection until 2042 and extensive insurance coverage in the U.S.

The most recent analyst rating on (CPIX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Cumberland Pharmaceuticals stock, see the CPIX Stock Forecast page.